Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

Zimmer Continuum Metal on Polyethylene (MoP) PostMarket Clinical Followup (PMCF) Study

← catalyst calendar

NCT01307384 · readout ≤ 499 d

Sponsored by Zimmer Biomet (industry) · ZBH — their whole pipeline →.

Phase
Status
Active, not recruiting
Study type
Observational
Enrollment
165actual
Sites
2
Country
United States

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis
DateFiledBasisWhat it is
Start2011-03-29actualWhen the study began enrolling
Primary completionDec 2027estimatedThe date the last participant is measured for the primary outcome — the readout window
Study completionDec 2027estimatedThe whole study's end, after follow-up
First posted2011-03-02estimatedWhen this record first appeared on the registry
Results postedWhen the sponsor posted results to the registry
Record updated2025-06-18actualThe sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Conditions

  • Avascular Necrosis
  • Osteoarthritis
  • Inflammatory Arthritis
  • Post-traumatic Arthritis
  • Rheumatoid Arthritis

Intervention

  • Device: Continuum Metal on Polyethylene Acetabular System — also filed as Total Hip Replacement, Total Hip Arthroplasty, Primary Hip

Primary outcomes

what the primary-completion date above is the date OF
Survivorship
measured 6 weeks, 6 months, 1 year, 2 year, 3 year, 5 year, 7 year, and 10 year
Safety / Adverse Events
measured Surgery, 6 weeks, 6 months, 1 year, 2 year, 3 year, 5 year, 7 year, and 10 year

Permalink · ZBH's whole pipeline · Catalyst calendar · Every registered study · What changed